KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Construction in Progress (2023 - 2025)

AbCellera Biologics' Construction in Progress history spans 3 years, with the latest figure at $118.7 million for Q3 2025.

  • For the quarter ending Q3 2025, Construction in Progress rose 670.78% year-over-year to $118.7 million, compared with a TTM value of $118.7 million through Sep 2025, up 670.78%, and an annual FY2024 reading of $103.2 million, up 13.41% over the prior year.
  • Construction in Progress for Q3 2025 was $118.7 million at AbCellera Biologics, up from $116.0 million in the prior quarter.
  • The five-year high for Construction in Progress was $118.7 million in Q3 2025, with the low at $10.5 million in Q2 2023.
  • Average Construction in Progress over 3 years is $51.4 million, with a median of $16.5 million recorded in 2024.
  • Year-over-year, Construction in Progress grew 13.41% in 2024 and then surged 792.31% in 2025.
  • Tracing ABCL's Construction in Progress over 3 years: stood at $91.0 million in 2023, then grew by 13.41% to $103.2 million in 2024, then increased by 15.02% to $118.7 million in 2025.
  • Per Business Quant, the three most recent readings for ABCL's Construction in Progress are $118.7 million (Q3 2025), $116.0 million (Q2 2025), and $17.6 million (Q1 2025).